Literature DB >> 30297520

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database.

Pietro Emiliano Doneddu1, Dario Cocito2, Fiore Manganelli3, Raffaella Fazio4, Chiara Briani5, Massimiliano Filosto6, Luana Benedetti7, Anna Mazzeo8, Girolama Alessandra Marfia9, Andrea Cortese10, Brigida Fierro11, Stefano Jann12, Ettore Beghi13, Angelo Maurizio Clerici14, Marinella Carpo15, Angelo Schenone16, Marco Luigetti17, Giuseppe Lauria18,19, Giovanni Antonini20, Tiziana Rosso21, Gabriele Siciliano22, Guido Cavaletti23, Giuseppe Liberatore1, Lucio Santoro3, Erdita Peci2, Stefano Tronci4, Marta Ruiz5, Stefano Cotti Piccinelli6, Antonio Toscano8, Giorgia Mataluni9, Laura Piccolo10, Giuseppe Cosentino11, Mario Sabatelli17,24, Eduardo Nobile-Orazio25,26.   

Abstract

OBJECTIVES: A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.
METHODS: We applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.
RESULTS: At the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 (18%) had atypical CIDP, including 34 (7%) with distal acquired demyelinating symmetric neuropathy (DADS), 17 (4%) with purely motor, 17 (4%) with Lewis-Sumner syndrome (LSS) and 16 (3.5%) with purely sensory CIDP. Based on retrospective review of the symptoms and signs present at onset and for at least 1 year, 180 (39%) patients had an initial diagnosis compatible with atypical CIDP that in 96 (53%) patients evolved to typical CIDP. Mean disease duration was longer in patients evolving to typical CIDP than in those not evolving (p=0.0016). Patients with DADS and LSS had a less frequent response to immunoglobulin than those with typical CIDP, while patients with purely motor and sensory CIDP had a similar treatment response.
CONCLUSIONS: The proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent response to intravenous immunoglobulin compared with typical CIDP, raising the possibility of a different underlying pathogenetic mechanism. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndrome

Year:  2018        PMID: 30297520     DOI: 10.1136/jnnp-2018-318714

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

Review 1.  The ataxic neuropathies.

Authors:  Stéphane Mathis; Fanny Duval; Antoine Soulages; Guilhem Solé; Gwendal Le Masson
Journal:  J Neurol       Date:  2020-06-15       Impact factor: 4.849

2.  Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.

Authors:  Malek Mansour; Amine Rachdi; Nesrine Baradai; Amel Kacem; Ines Bedoui; Ridha Mrissa
Journal:  Neurol Sci       Date:  2021-05-04       Impact factor: 3.307

3.  Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database.

Authors:  Giuseppe Liberatore; Alberto De Lorenzo; Claudia Giannotta; Fiore Manganelli; Massimiliano Filosto; Giuseppe Cosentino; Dario Cocito; Chiara Briani; Andrea Cortese; Raffaella Fazio; Giuseppe Lauria; Angelo Maurizio Clerici; Tiziana Rosso; Girolama Alessandra Marfia; Giovanni Antonini; Guido Cavaletti; Marinella Carpo; Pietro Emiliano Doneddu; Emanuele Spina; Stefano Cotti Piccinelli; Erdita Peci; Luis Querol; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2022-01-20       Impact factor: 3.307

Review 4.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 5.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

6.  Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.

Authors:  Juliane Klehmet; Svenja Beutner; Sarah Hoffmann; Matthias Dornauer; Friedemann Paul; Ralf Reilmann; Alexander U Brandt; Andreas Meisel
Journal:  BMC Neurol       Date:  2019-06-08       Impact factor: 2.474

7.  Chronic inflammatory demyelinating polyneuropathy with hypoglossal nerve involvement and inverted Beevor's sign: case report.

Authors:  Huajian Zhao; Yiming Zheng; Lingchao Meng; Meng Yu; Wei Zhang; He Lv; Zhaoxia Wang; Hongjun Hao; Yun Yuan
Journal:  BMC Neurol       Date:  2021-06-26       Impact factor: 2.474

Review 8.  The Misdiagnosis of CIDP: A Review.

Authors:  Jeffrey A Allen
Journal:  Neurol Ther       Date:  2020-03-26

9.  Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

Authors:  Andrea Cortese; Raffaella Lombardi; Chiara Briani; Ilaria Callegari; Luana Benedetti; Fiore Manganelli; Marco Luigetti; Sergio Ferrari; Angelo M Clerici; Girolama Alessandra Marfia; Andrea Rigamonti; Marinella Carpo; Raffaella Fazio; Massimo Corbo; Anna Mazzeo; Fabio Giannini; Giuseppe Cosentino; Elisabetta Zardini; Riccardo Currò; Matteo Gastaldi; Elisa Vegezzi; Enrico Alfonsi; Angela Berardinelli; Ludivine Kouton; Constance Manso; Claudia Giannotta; Pietro Doneddu; Patrizia Dacci; Laura Piccolo; Marta Ruiz; Alessandro Salvalaggio; Chiara De Michelis; Emanuele Spina; Antonietta Topa; Giulia Bisogni; Angela Romano; Sara Mariotto; Giorgia Mataluni; Federica Cerri; Claudia Stancanelli; Mario Sabatelli; Angelo Schenone; Enrico Marchioni; Giuseppe Lauria; Eduardo Nobile-Orazio; Jérôme Devaux; Diego Franciotta
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-11-21

Review 10.  Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.

Authors:  Haruki Koike; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2020-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.